Exact Mass: 472.2321732
Exact Mass Matches: 472.2321732
Found 500 metabolites which its exact mass value is equals to given mass value 472.2321732
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Lucidenic acid K
Lucidenic acid K is found in mushrooms. Lucidenic acid K is a constituent of Ganoderma lucidum (reishi) Constituent of Ganoderma lucidum (reishi). Lucidenic acid K is found in mushrooms. Lucidenic acid K is a triterpenoid.
Chenodeoxycholic acid sulfate
C24H40O7S (472.24946100000005)
The sulfate salt of Chenodeoxycholic acid is one of the 4 main organic acids produced by the liver. (Wikipedia). The sulfate salt of Chenodeoxycholic acid is one of the 4 main organic acids produced by the liver. [HMDB]
Chenodeoxycholic acid 3-sulfate
C24H40O7S (472.24946100000005)
Chenodeoxycholic acid 3-sulfate is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID:16949895) [HMDB] Chenodeoxycholic acid 3-sulfate is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID: 16949895). D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Ursodeoxycholic acid 3-sulfate
C24H40O7S (472.24946100000005)
Ursodeoxycholic acid is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID:16949895) [HMDB] Ursodeoxycholic acid is produced by the action of enzymes existing in the microbial flora of the colonic environment. The major phase II metabolism of bile acids is sulfation mainly catalyzed by the hydroxysteroid sulfotransferase, forming the 3-sulfate conjugate. (PMID: 16949895).
2-Hydroxy-imipramine glucuronide
2-Hydroxy-imipramine glucuronide is a metabolite of imipramine. Imipramine (sold as Antideprin, Deprimin, Deprinol, Depsol, Depsonil, Dynaprin, Eupramin, Imipramil, Irmin, Janimine, Melipramin, Surplix, Tofranil), also known as melipramine, is an antidepressant medication, a tricyclic antidepressant of the dibenzazepine group. Imipramine is mainly used in the treatment of major depression and enuresis (inability to control urination). It has also been evaluated for use in panic disorder. (Wikipedia)
Lexaptepid pegol
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent C274 - Antineoplastic Agent > C129821 - Antineoplastic Biological Agent C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C307 - Biological Agent
Linagliptin
Methylprednisolone aceponate
3-Ketopetromyzonol sulfate
C24H40O7S (472.24946100000005)
20-O-Acetylingenol-3-angelate
Euchrenone a15
13-(acetyloxy)-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl (2E)-2-methylbut-2-enoate
20-Deoxy,16-acetoxy,3-angeloyl-Ingenol|20-deoxy-16-hydroxyingenol-16-acetate-3-angelate
(+/-)-3-[(2E,6E,10E)-11-carboxy-13-hydroxy-3,7,15-trimethyl-2,6,10,14-hexadecatetraenyl]-4,5-dihydroxybenzoic acid
(1R*,2R*,5Z,10R*,11S*,12R*,14S*)-14-acetoxy-11,12-epoxy-3-oxobriara-5,7,17-trien-2-yl 3-methylbutanoate
2-{[(5S)-5,6,7,8-tetrahydro-9-hydroxy-3,5-dimethylnaphthol[2,3-b]furan-4-yl]methyl}-3,5-dimethyl-6-[(3E)-pent-3-en-1-yl]-1-benzofuran-4,7-dione
5-hydroxy-8-methyl-6-(2-methylbutanoyl)-8-(4-methylpent-3-enyl)-4-phenyl-2h-pyrano[2,3-h]chromen-2-one
longipin-2-ene-7beta-acetyloxy-9alpha-senecioyloxy-15-angeloyloxy-1-one
5-formyloxy-3,4-dimethoxy-benzoic acid 11-oxo-dodecahydro-7,14-methano-dipyrido[1,2-a;1,2-e][1,5]diazocin-2-yl ester|Formylcinegallein
12-O-[3-methyl-2-butenoyl]-4-deoxyphorbol 13-acetate
7beta,9alpha-diangeloyloxy-8alpha-acetyloxylongipin-2-en-1-one
longipin-2-ene-7beta-acetyloxy-9alpha,15-diangeloyloxy-1-one
(+/-)-3-[(2E,6E,10E)-11-carboxy-14-hydroxy-3,7,15-trimethyl-2,6,10,15-hexadecatetraenyl]-4,5-dihydroxybenzoic acid
Linagliptin
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
C27H36O7_2-Butenoic acid, 2-methyl-, 9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-7b-hydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa[3,4]benz[1,2-e]azulen-9-yl ester, (2E)
3Alpha-Hydroxy-3-Deoxyangolensic Acid Methyl Ester
3a-Sulfooxy-7a-OH-5b-cholanic acid
C24H40O7S (472.24946100000005)
BA-140-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-140-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-140-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-140-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
SCDCA - Sulfochenodeoxycholic acid
C24H40O7S (472.24946100000005)
13-(acetyloxy)-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl (2E)-2-methylbut-2-enoate_major
3-Deoxy-3Beta-Hydroxyangolensic Acid Methyl Ester_major
(4R)-4-((3R,5R,8R,9S,10S,12S,13R,17R)-12-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
C24H40O7S (472.24946100000005)
(4R)-4-((3R,5R,7R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-(sulfooxy)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
C24H40O7S (472.24946100000005)
13-(acetyloxy)-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,?.0¹¹,¹³]pentadeca-3,8-dien-14-yl (2E)-2-methylbut-2-enoate
Ala Phe His Val
Ala Phe Val His
Ala His Phe Val
Ala His Val Phe
Ala Val Phe His
Ala Val His Phe
Asp Glu Ile Pro
Asp Glu Leu Pro
Asp Glu Pro Ile
Asp Glu Pro Leu
Asp Ile Glu Pro
Asp Ile Pro Glu
Asp Lys Asn Pro
C19H32N6O8 (472.22815119999996)
Asp Lys Pro Asn
C19H32N6O8 (472.22815119999996)
Asp Leu Glu Pro
Asp Leu Pro Glu
Asp Asn Lys Pro
C19H32N6O8 (472.22815119999996)
Asp Asn Pro Lys
C19H32N6O8 (472.22815119999996)
Asp Pro Glu Ile
Asp Pro Glu Leu
Asp Pro Ile Glu
Asp Pro Lys Asn
C19H32N6O8 (472.22815119999996)
Asp Pro Leu Glu
Asp Pro Asn Lys
C19H32N6O8 (472.22815119999996)
Glu Asp Ile Pro
Glu Asp Leu Pro
Glu Asp Pro Ile
Glu Asp Pro Leu
Glu Glu Pro Val
Glu Glu Val Pro
Glu Ile Asp Pro
Glu Ile Pro Asp
Glu Leu Asp Pro
Glu Leu Pro Asp
Glu Pro Asp Ile
Glu Pro Asp Leu
Glu Pro Glu Val
Glu Pro Ile Asp
Glu Pro Leu Asp
Glu Pro Val Glu
Glu Val Glu Pro
Glu Val Pro Glu
Phe Ala His Val
Phe Ala Val His
Phe Gly His Ile
Phe Gly His Leu
Phe Gly Ile His
Phe Gly Leu His
Phe His Ala Val
Phe His Gly Ile
Phe His Gly Leu
Phe His Ile Gly
Phe His Leu Gly
Phe His Val Ala
Phe Ile Gly His
Phe Ile His Gly
Phe Leu Gly His
Phe Leu His Gly
Phe Val Ala His
Phe Val His Ala
Gly Phe His Ile
Gly Phe His Leu
Gly Phe Ile His
Gly Phe Leu His
Gly His Phe Ile
Gly His Phe Leu
Gly His Ile Phe
Gly His Leu Phe
Gly Ile Phe His
Gly Ile His Phe
Gly Leu Phe His
Gly Leu His Phe
His Ala Phe Val
His Ala Val Phe
His Phe Ala Val
His Phe Gly Ile
His Phe Gly Leu
His Phe Ile Gly
His Phe Leu Gly
His Phe Val Ala
His Gly Phe Ile
His Gly Phe Leu
His Gly Ile Phe
His Gly Leu Phe
His Ile Phe Gly
His Ile Gly Phe
His Leu Phe Gly
His Leu Gly Phe
His Val Ala Phe
His Val Phe Ala
Ile Asp Glu Pro
Ile Asp Pro Glu
Ile Glu Asp Pro
Ile Glu Pro Asp
Ile Phe Gly His
Ile Phe His Gly
Ile Gly Phe His
Ile Gly His Phe
Ile His Phe Gly
Ile His Gly Phe
Ile Pro Asp Glu
Ile Pro Glu Asp
Lys Asp Asn Pro
C19H32N6O8 (472.22815119999996)
Lys Asp Pro Asn
C19H32N6O8 (472.22815119999996)
Lys Asn Asp Pro
C19H32N6O8 (472.22815119999996)
Lys Asn Pro Asp
C19H32N6O8 (472.22815119999996)
Lys Pro Asp Asn
C19H32N6O8 (472.22815119999996)
Lys Pro Asn Asp
C19H32N6O8 (472.22815119999996)
Leu Asp Glu Pro
Leu Asp Pro Glu
Leu Glu Asp Pro
Leu Glu Pro Asp
Leu Phe Gly His
Leu Phe His Gly
Leu Gly Phe His
Leu Gly His Phe
Leu His Phe Gly
Leu His Gly Phe
Leu Pro Asp Glu
Leu Pro Glu Asp
Asn Asp Lys Pro
C19H32N6O8 (472.22815119999996)
Asn Asp Pro Lys
C19H32N6O8 (472.22815119999996)
Asn Lys Asp Pro
C19H32N6O8 (472.22815119999996)
Asn Lys Pro Asp
C19H32N6O8 (472.22815119999996)
Asn Pro Asp Lys
C19H32N6O8 (472.22815119999996)
Asn Pro Lys Asp
C19H32N6O8 (472.22815119999996)
Asn Pro Arg Ser
Asn Pro Ser Arg
Asn Arg Pro Ser
Asn Arg Ser Pro
Asn Ser Pro Arg
Asn Ser Arg Pro
Pro Asp Glu Ile
Pro Asp Glu Leu
Pro Asp Ile Glu
Pro Asp Lys Asn
C19H32N6O8 (472.22815119999996)
Pro Asp Leu Glu
Pro Asp Asn Lys
C19H32N6O8 (472.22815119999996)
Pro Glu Asp Ile
Pro Glu Asp Leu
Pro Glu Glu Val
Pro Glu Ile Asp
Pro Glu Leu Asp
Pro Glu Val Glu
Pro Ile Asp Glu
Pro Ile Glu Asp
Pro Lys Asp Asn
C19H32N6O8 (472.22815119999996)
Pro Lys Asn Asp
C19H32N6O8 (472.22815119999996)
Pro Leu Asp Glu
Pro Leu Glu Asp
Pro Asn Asp Lys
C19H32N6O8 (472.22815119999996)
Pro Asn Lys Asp
C19H32N6O8 (472.22815119999996)
Pro Asn Arg Ser
Pro Asn Ser Arg
Pro Pro Pro Tyr
Pro Pro Tyr Pro
Pro Gln Gln Thr
C19H32N6O8 (472.22815119999996)
Pro Gln Thr Gln
C19H32N6O8 (472.22815119999996)
Pro Arg Asn Ser
Pro Arg Ser Asn
Pro Ser Asn Arg
Pro Ser Arg Asn
Pro Thr Gln Gln
C19H32N6O8 (472.22815119999996)
Pro Val Glu Glu
Pro Tyr Pro Pro
Gln Pro Gln Thr
C19H32N6O8 (472.22815119999996)
Gln Pro Thr Gln
C19H32N6O8 (472.22815119999996)
Gln Gln Pro Thr
C19H32N6O8 (472.22815119999996)
Gln Gln Thr Pro
C19H32N6O8 (472.22815119999996)
Gln Thr Pro Gln
C19H32N6O8 (472.22815119999996)
Gln Thr Gln Pro
C19H32N6O8 (472.22815119999996)
Arg Asn Pro Ser
Arg Asn Ser Pro
Arg Pro Asn Ser
Arg Pro Ser Asn
Arg Ser Asn Pro
Arg Ser Pro Asn
Ser Asn Pro Arg
Ser Asn Arg Pro
Ser Pro Asn Arg
Ser Pro Arg Asn
Ser Arg Asn Pro
Ser Arg Pro Asn
Thr Pro Gln Gln
C19H32N6O8 (472.22815119999996)
Thr Gln Pro Gln
C19H32N6O8 (472.22815119999996)
Thr Gln Gln Pro
C19H32N6O8 (472.22815119999996)
Val Ala Phe His
Val Ala His Phe
Val Glu Glu Pro
Val Glu Pro Glu
Val Phe Ala His
Val Phe His Ala
Val His Ala Phe
Val His Phe Ala
Val Pro Glu Glu
Tyr Pro Pro Pro
Ursodeoxycholate 3-sulfate
C24H40O7S (472.24946100000005)
BAY-u9773
C27H36O5S (472.22833260000004)
Lucidenic acid K
9a-Acetoxy-7b-hydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1H-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl (2E)-2-methyl-2-butenoate
ST 24:1;O4;S
C24H40O7S (472.24946100000005)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
SCHROCK ALKYNE METATHESIS CATALYST
C17H36O3W (472.21738360000006)
Pacritinib
C28H32N4O3 (472.24742819999994)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EJ - Janus-associated kinase (jak) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Methylprednisolone aceponate
D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AC - Corticosteroids, potent (group iii) C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D000893 - Anti-Inflammatory Agents
4-N-[4-(4-amino-N-(4-aminophenyl)anilino)phenyl]-4-N-(4-aminophenyl)benzene-1,4-diamine
8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
B5R5IQ1D64
COVID info from PDB, Protein Data Bank Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
7-(3,4-dimethoxyphenyl)-4-methyl-2-[4-(phenylmethyl)-1-piperazinyl]-7,8-dihydro-6H-quinazolin-5-one
C28H32N4O3 (472.24742819999994)
[1-[[(2R,3R,4S,5S)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]azanium
4-{[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanyl}benzoic acid
C27H36O5S (472.22833260000004)
SuvanineS sodium salt
C25H37NaO5S (472.22592720000006)
A natural product found in Coscinoderma species.
3alpha-Sulfooxy-12alpha-hydroxy-5beta-cholan-24-oic acid
C24H40O7S (472.24946100000005)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
[13-acetyloxy-1-hydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] (E)-2-methylbut-2-enoate
Puromycin(1+)
Puromycin monoprotonated at the amino nitrogen. It is the predominant species at pH 7.3.
(3R,4R)-N-[3-(dimethylamino)propyl]-3-[4-(hydroxymethyl)phenyl]-2-(5-methyl-2-pyridinyl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
C28H32N4O3 (472.24742819999994)
[(1R)-7-methoxy-9-methyl-1-[(5-phenyl-3-isoxazolyl)methyl]-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C28H32N4O3 (472.24742819999994)
1-[[(2R,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2R,3R)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3R)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2R,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-isoxazolecarboxamide
1-(3-fluorophenyl)-3-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(4S,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4S,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4R,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
1-(3-fluorophenyl)-3-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
[(1S)-7-methoxy-9-methyl-1-[(5-phenyl-3-isoxazolyl)methyl]-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
C28H32N4O3 (472.24742819999994)
1-[[(2S,3S)-8-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-3-(4-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2S,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3R)-8-(2-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-(3-fluorophenyl)-3-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(2-fluorophenyl)-3-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(4R,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4R,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4R,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4S,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(4S,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
1-(3-fluorophenyl)-3-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3-fluorophenyl)-3-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]-N-[2-(1-pyrrolidinyl)ethyl]acetamide
[(1R)-2-[(4-fluorophenyl)methyl]-7-methoxy-1-(2-pyridinylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C28H29FN4O2 (472.22744259999996)
[(1S)-2-[(4-fluorophenyl)methyl]-7-methoxy-1-(2-pyridinylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C28H29FN4O2 (472.22744259999996)
methyl 2-[(1S,3S,5R,7S,8S,9S,12S,13S)-13-(furan-3-yl)-5-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.01,12.03,8]heptadecan-7-yl]acetate
(1-acetyloxy-3-phosphonooxypropan-2-yl) (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
(1-butanoyloxy-3-phosphonooxypropan-2-yl) (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
PF-00835231
A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity.